Target family: Voltage-gated calcium channels  (Ca<sub>V</sub>) (type: vgic)
Target: Ca<sub>v</sub>2.2

Ligand: cilnidipine (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons.
Published in: J Pharmacol Exp Ther

Ligand: DW13.3 (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Inhibition of neuronal calcium channels by a novel peptide spider toxin, DW13.3.
Published in: Mol Pharmacol

Ligand: kurtoxin (Peptide)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Median affinity: 6.3 pEC50
Reference (Journal): Kurtoxin, a gating modifier of neuronal high- and low-threshold ca channels.
Published in: J Neurosci

Ligand: NP118809 (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Journal): Scaffold-based design and synthesis of potent N-type calcium channel blockers.
Published in: Bioorg Med Chem Lett

Ligand: ω-conotoxin CVIA (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 9.3 pIC50
Reference (Journal): Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes.
Published in: J Biol Chem

Ligand: ω-conotoxin CVIB (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 8.1 pIC50
Reference (Journal): Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes.
Published in: J Biol Chem

Ligand: ω-conotoxin CVIC (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 8.1 pIC50
Reference (Journal): Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes.
Published in: J Biol Chem

Ligand: ω-conotoxin CVID (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.199999809265137 pIC50
Reference (Journal): Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes.
Published in: J Biol Chem

Ligand: ω-conotoxin GVIA (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.399999618530273 pIC50
Reference (Journal): Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes.
Published in: J Biol Chem

Ligand: ω-conotoxin MVIIC (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes.
Published in: J Biol Chem

Ligand: ω-conotoxin MVIIC (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): A new Conus peptide ligand for mammalian presynaptic Ca2+ channels.
Published in: Neuron

Ligand: ω-conotoxin MVIIC (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Inhibition of calcium channels in rat central and peripheral neurons by omega-conotoxin MVIIC.
Published in: J Neurosci

Ligand: ω-grammotoxin SIA (Peptide)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Voltage-dependent inhibition of N- and P-type calcium channels by the peptide toxin omega-grammotoxin-SIA.
Published in: Mol Pharmacol

Ligand: Pb2+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Median affinity: 5.9 pIC50
Reference (Journal): Characteristics of block by Pb2+ of function of human neuronal L-, N-, and R-type Ca2+ channels transiently expressed in human embryonic kidney 293 cells.
Published in: Mol Pharmacol

Ligand: TROX-1 (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker.
Published in: J Pharmacol Exp Ther

Ligand: TROX-1 (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Characterization of the substituted N-triazole oxindole TROX-1, a small-molecule, state-dependent inhibitor of Ca(V)2 calcium channels.
Published in: Mol Pharmacol

Ligand: ziconotide (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2004), EMA (2005)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR.
Published in: Biochem Pharmacol

Ligand: ziconotide (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2004), EMA (2005)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes.
Published in: J Biol Chem

Ligand: ziconotide (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2004), EMA (2005)
Median affinity: 1 pIC50
Reference (Journal): Identification and characterization of novel human Ca(v)2.2 (alpha 1B) calcium channel variants lacking the synaptic protein interaction site.
Published in: J Neurosci